tbuckley/cabot-search huggingface dataset:
Individualizse the treatment of liver metastases from colorectal cancer using RAND appropriateness method: Oncosurge decision model. Results of a consensus detecting from the international taskforce group
Authors: G. Poston, D. Haller, J. Kahan, M. Cornelis, S. Mahyaoui
Journal: Journal of Clinical Oncology (2004)

3595 Background: Less than 20% of patients with colorectal liver metastases (CLM) are suitable for liver resection with curative intent. Recent studies suggested that the use of oxaliplatin based neoadjuvant chemotherapy may increase this figure to 30–40% of all patients. However, there is no consensus that determine which patients might benefit from such chemotherapy and subsequently have the chance of coming to curative liver surgery. It will be many years before clinical trials addressing this question are able to report. The aim of this project was to create a therapeutic decision model using the RAND Appropriateness Method. Methods: Following a comprehensive literature review, an international panel of liver surgeons, oncologists and radiologists (16 in total) provided both quantitative and qualitative expressions of opinion concerning the resectability of CLM. During 2 panel meetings a consensus was detected regarding specific patient characteristics in decision making for CLM resection. These characteristics are: contraindications; primary tumour characteristics and CLM characteristics. All characteristics were applied to appropriateness relating to resection and chemotherapy. The appropriateness of each therapeutic decision was assessed by the panel for all possible patient scenarios. Results: Consensus was agreed that features which totally pre-clude consideration for resection included not-treatable extra-hepatic disease, unfit for surgery, CLM involvement of >70% liver or 6 segments. Optimal type (5FU/LV, oxaliplatin, irinotecan) and sequences of chemotherapy pre and post resectability were evaluated. Other specific data relating to CLM (number and size of mets, resection margin, portal nodes) will be presented. Conclusions: This validated decision model tool would help healthcare providers to analyse the appropriateness of liver resection alone or in association with optimal chemotherapeutic sequence based upon individual patient and tumour characteristics. This tool will be available on academic website. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi-Synthelabo Evidis Sarl; Pfizer; Sanofi-Synthelabo Pfizer; Sanofi-Synthelabo Sanofi-Synthelabo Sanofi-Synthelabo
Development of a blood based breast cancer test for Indian population.
Authors: D Tobin, K Bårdsen, T Lindahl, M Kauczynska, D Punia, Y Kumar, C Desai, C Shroff, A Børresen-Dale, P Sharma
Journal: Cancer Research (2009)

Abstract Abstract #5013 Background: The incidence of breast cancer (BC) in India is increasing as the society becomes more westernized. No national screening program exists and there is a high mortality rate which may be linked to the late detection of the disease. Here we report the development of a gene expression based blood test to detect BC. We have previously presented data from European/US cohort with accuracies ranging between 75% - 82% suggesting that test can be developed to early detect breast cancer. We now report the findings from a multi-centre study initiated to test the efficacy of the test for early detection of breast cancer (BC) in an Indian population.&amp;#x2028; Methods: A multicentre-study was initiated where blood samples were collected from women recruited in 5 different groups 1) early stage BC, 2) late stage BC, 3) women at high risk - without BC, 4) benign breast lesions, 5) without abnormal mammographic findings. The women recruited in group 3 is a part of ongoing prospective study. Recruitment was balanced between pre- and post-menopausal women among the remaining groups. Samples were collected in PAXgene tubes and shipped to a central laboratory where RNA extraction and quality control. Gene expression analysis was performed using TaqMan® low density arrays (LDA's) containing a BC-specific gene signature in a 96-gene assay format. A total of 442 samples from groups 1, 2, 4 and 5 were used to develop the India model and estimate its prediction efficacy. The 442 samples were divided between a training cohort (N=292) and a test cohort (N=150). Gene expression data of the training cohort were used to develop the breast cancer specific diagnostic model and its performance was determined by predicting the class of the independent test cohort.&amp;#x2028; Results: The developed model correctly predicted the class of 110/150 test samples, resulting in an overall accuracy of 73%. Prediction performance was similar for early and late stage cancer and for benign and healthy (no mammographic findings). No significant difference in diagnostic performance was seen between pre- (57/75 correctly predicted) and post-menopausal (53/75 correctly predicted) women indicating the clinical value of our test in younger women.&amp;#x2028; Conclusion: The Indian multi-centre study demonstrates the utility of the BC-specific 96 assay signature in detecting BC in an Indian population with similar diagnostic performance seen between women with late stage (stage 2+) and early stage BC. We have previously presented data from European and US cohorts with similar diagnostic performance suggesting the broad applicability of our test. The Breast Cancer test showed the same high level of accuracy in pre-menopausal as in post-menopausal women indicating its clinical applicability in younger women where mammography is of less value due to dense breast tissue. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5013.
GATED SPIN ECHO NMR IMAGING FOR NONINVASIVE IN-VIVO QUANTITATION OF LEFT VENTRICULAR MASS IN MAN.
Authors: Enrique Ostrzega, Jamshid Maddahi, Hiroshi Honma, John Crues, Joseph Fraire, Yzhar Charuzi, Daniel Berman
Journal: Clinical Nuclear Medicine (1987)

Ostrzega, Enrique; Maddahi, Jamshid; Honma, Hiroshi; Crues, John; Fraire, Joseph; Charuzi, Yzhar; Berman, Daniel Author Information
THE IMPACT OF SERUM TRANS FATTY ACIDS CONCENTRATION ON PLAQUE VULNERABILITY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDER MANAGEMENT OF CONVENTIONAL RISK FACTORS: ASSESSMENT VIA OPTICAL COHERENCE TOMOGRAPHY
Authors: Yoshinori Nagasawa, Toshiro Shinke, Ryuji Toh, Hiromasa Otake, Tomofumi Takaya, Takayoshi Toba, Masaru Kuroda, Hachidai Takahashi, Daisuke Terashita, Kenzo Uzu, Daiji Kashiwagi, Koji Kuroda, Yuto Shinkura, Natsuko Tahara, Hiroyuki Yamamoto, Yoshiro Tsukiyama, Kenichi Yanaka, Yuichiro Nagano, Tatsuro Ishida, Ken-Ichi Hirata
Journal: Journal of the American College of Cardiology (2016)
Abstract 3949: Micro-RNA regulated EGFR expression in head and neck squamous cell carcinoma
Authors: Belinda R. Hauser, Joseph Califano, Xinbin Gu, Yubin Hao
Journal: Cancer Research (2011)

Abstract Purpose: Each year in the United States there are more than 65,000 Americans diagnosed with head and neck cancer and 25,000 die from this disease. Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with complex molecular abnormalities, including overexpression of epidermal growth factor receptor (EGFR). The overexpression of EGFR is seen in 80-90% of HNSCC cases and has been shown to be an indicator of poor prognosis and survival in oral cancer patients. The molecular mechanism of EGFR gene expression is poorly understood in HNSCC. MicroRNAs are a new class of posttranslational regulators of gene expression and are a useful target in understanding EGFR gene expression in HNSCC. We hypothesize that microRNAs may play an important role in EGFR gene overexpression during HNSCC processes. Design Methods: We generated stably expressing exogenous miRNA-7 or miRNA-128 in cell lines (JHU-06,-011,-013,-019, -022, and -029 using lentivirus infection, performed colony formation assays to determine cell growth and proliferation, QRT-PCR to analyze gene expression, and Western blot analysis to evaluate protein expression. Results: We found that the miR-7 and -128 transfection efficiency were quite different in these six cell lines. The transfected cell lines stably expressed exogenous miR-7 or -128. Compared with the control cells, the levels of EGFR protein and cell viability were significantly lower in miR-7, -128 transfected HNSCC cell lines. CONCLUSION: We successfully constructed the stably expressing exogenous miR-7, -128 HNSCC cell lines and validated that miR-7,-128 can down-regulate EGFR expression by specifically targeting the EGFR mRNA 3’UTR. MiR-7 and miR-128 have potential to serve as a therapeutic approach to specifically target EGFR in HNSCC. This work was supported in part by grants P20 CA118770 from National Cancer Institute. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3949. doi:10.1158/1538-7445.AM2011-3949
Altered Radiopharmaceutical Distribution in Myeloma
Authors: ASHOK K. GUPTA, PHILIPP MEYER, MILTON D. GROSS, LORRAINE M. FIG, BRAHM SHAPIRO
Journal: Clinical Nuclear Medicine (1998)

Tissue deposits of amyloid may lead to various clinical symptoms and signs, depending on the site of deposition. In addition, a specific subtype of amyloidosis, AL protein type, is associated with multiple myeloma. Two cases representing contrasting examples of altered radiopharmaceutical biodistribution in myeloma and amyloidosis are presented and discussed, with a bone tracer depicting the heart and a heart tracer depicting the bones.
PTU-082 Paediatric Inflammatory Bowel Disease Unclassified In Scotland: Incidence And Natural History
Authors: FL Cameron, P Henderson, RK Russell, DC Wilson
Journal: Gut (2014)

<h3>Introduction</h3> Inflammatory Bowel Disease Unclassified (IBDU) accounts for ~10% of paediatric IBD (PIBD). The natural history of IBDU includes potential evolution to Crohn’s disease (CD) or ulcerative colitis (UC). Few epidemiologically robust studies of IBDU exist so we aimed to describe the incidence and the natural history of paediatric IBDU in a population-based cohort. <h3>Methods</h3> Incidence of IBDU was collected over a 10-year period (01/03–12/12) from the two largest Scottish paediatric gastroenterology networks (serving 74.4% of Scottish population &lt;16 years). Demographics, diagnostic investigation and follow-up data were obtained until study end (31.10.13; unless prior transition or emigration) to ascertain reclassification of IBD subtype, clinical progress and outcome at last follow up. Incidence rates and trends were calculated using publicly available population data and statistics generated using Poisson regression. <h3>Results</h3> 65 patients were IBDU (57% male) at diagnosis with a median age of 11.3yrs (range 2.6–15.9). The age adjusted incidence of IBDU was 0.65/100,000/yr (95% CI 0.42–0.97) in the 5-year epoch 2003–2007 and 1.14/100,000/yr (95% CI 0.81–1.56) for 2008–2012, a non-significant increase (p = 0.068). All patients had colonoscopy (74% ileal intubation), 62 (95%) had an upper GI endoscopy; remaining 3 had small bowel imaging. 61 (94%) had radiological imaging, 44 (68%) had a barium meal and follow through with 15 (23%) having MR enterography. At diagnosis, 53 (82%) had a pancolitis, 4 (6%) had disease distal to the hepatic flexure, 5 (8%) had disease distal to the splenic flexure and 3 (4%) had proctitis. 37 (57%) had mild disease (defined as mild infrequent relapses) while 7 (11%) had severe chronically active disease with 5 (8%) requiring Infliximab. Median follow-up was 3.1 yrs (range 0.4–6.8). 16 (25%) had their diagnosis changed (all after endoscopic re-evaluation) after a median of 1.6yrs (range 0.6–5.7), to CD in 11 and UC in 5; 10 (15%) remained IBDU. 3 (4%) required surgery and had colectomy and end ileostomy, 2 (66%) had diagnosis changed to UC prior to surgery whilst the other remained IBDU and reclassified to CD later. <h3>Conclusion</h3> In the first ever UK population-based epidemiological study of IBDU, the incidence of IBDU demonstrated a non-significant trend to rise during the 10 year study period. 25% of patients had their diagnosis changed after endoscopic re-evaluation, more than previously reported by systematic review (Prenzel and Uhlig JCC 2009) after median follow up of 1.6 years. Most cases had inactive/mild disease activity; a minority remained IBDU despite re-assessment. <h3>Disclosure of Interest</h3> None Declared.
Abstract 4134: Exploration for possible predictive biomarkers for individual response to mFOLFOX6 in colorectal cancer patients
Authors: Okihide Suzuki, Kohei Murata, Mutsumi Fukunaga, Hiroyoshi Takemoto, Masayuki Ohue, Rikuko Ikeda, Satoru Wada, Hidetaka Eguchi, Naohiro Tomita, Masahiko Watanabe, Hideyuki Ishida, Masahiko Nishiyama
Journal: Cancer Research (2011)

Abstract Background: Incorporation of molecular targeting agents such as bevacizumab, cetuximub, and panitumumab, into cytotoxic chemotherapeutic regimens has increased survival in colorectal cancer patients, resulted in provision of a promising means of individualization of these therapies. Nonetheless, the clinical efficacy and toxicity of basic regimens, such as FOLFIRI and FOLFOX, remain unpredictable. Thus, identification of molecular indicators of individual response to the basic regimens is urgently required. Methods: This prospective study was conducted to determine potent predictive markers of individual response to mFOLFOX6, in terms of efficacy and toxicity. Chemonaive patients with stage IV colorectal cancer were eligible for this trial after a palliative operation, and received mFOLFOX6 treatment. Along with a search for KRAS gene somatic mutations, analyses of mRNA expression levels in cancerous portions were conducted for 10 candidate marker genes, namely DPYD, TYMS, ERCC1, ERCC2, XRCC1, GSTP1, EGFR, VEGF, TYMP and TNFRSF1B, by means of real-time RT-PCR. In addition, some acknowledged polymorphisms of DPYD, TYMS, ERCC1, ERCC2, XRCC1, GSTP1 and EGFR genes were also determined. Results: Fifty pts received a total of 424 treatment cycles. Overall response rate was 60.4% (1CR and 28 PRs), and median overall and progression survival were 930 days and 234 days, respectively. The most common grade 3/4 toxicity was neutropenia (40%), followed by anorexia (6%), anemia (4%), leucopenia (4%), etc. The therapeutic response was not related to KRAS somatic mutational status, and no genotype-toxicity association was observed, thus far tested. On the other hand, ERCC1, ERCC2, and TYMS gene expression levels were significantly higher in patients with PD than in those with CR/PR/SD (P=0.017, 0.028, and 0.032, respectively). The expression levels of TYMS were highly correlative with best tumor response rate (R=0.414, P=0.004). Overall survival was significantly better in patients with low ERCC2 expression (P=0.039). Furthermore, combined expression levels of ERCC1, ERCC2, and TYMS were found to be associated with PFS: Those patients with high expression levels of all of these 3 genes showed poorer survival than the others (P=0.0029). Conclusions: Expression levels of ERCC1, ERCC2, and TYMS genes in tumor may be predictable for individual response to mFOLFOX6. A large-scale prospective study to validate their predictive values is now under planning. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4134. doi:10.1158/1538-7445.AM2011-4134
Abstract 16540: Impact of Baseline Stroke Risk and Bleeding Risk on INR Control among Patients with Atrial Fibrillation on Warfarin: the TREAT-AF Study
Authors: Mintu P Turakhia, Claire T Than, Xiangyan Xu, Susan K Schmitt, Felix Yang, Susan M Frayne, Ciaran S Phibbs, Tyson H Holmes, Paul A Heidenreich
Journal: Circulation (2012)

Background: In atrial fibrillation (AF), time in INR therapeutic range of 2.0-3.0 (TTR) mediates stroke reduction and bleeding risk with warfarin. Comorbidities may affect ability to achieve adequa...
Issues Remain for Treating Colorectal Cancer
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Issues Remain for Treating Colorectal Cancer Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 7, 5 April 1995, Page 480, https://doi.org/10.1093/jnci/87.7.480 Published: 05 April 1995
AB0058 Cytokine secretion and cytotoxic activity of natural killer cells in behÇet’s disease
Authors: F. Cosan, E. Aktas-Cetin, N. Akdeniz, Z. Emrence, F. Gecgel, G. Erbag, A. Dogru, G. Deniz, A. Cefle
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Behcet's disease (BD) is a multi-system inflammatory disorder with recurrent inflammation attacks. BD pathogenesis includes genetical, environmental and immunological factors. The main genetic susceptibility is HLA-B*51, but the mechanism is unknown. HLA molecules play a key role with the interaction with natural killer (NK) cells which are one of the components of the innate immune system. They have the ability to both lyse target cells and serve as regulators of immune responses by releasing Th1, Th2 and Th17 type cytokines. <h3>Objectives</h3> In this study, cytokine secretion and cytotoxic activity of NK cells in BD were investigated. <h3>Methods</h3> The study group consists of BD patients (n=26, mean age=37.2±9.7) with mucocutaneous involvement and healthy subjects (n=12, mean age=32.5±8). The patients had not received any immunsupresive treatment. Peripheral blood mononuclear cells (PBMC) were used as effector cells and K562 cell line was used as target cell. PBMCs stained with CD107a were incubated with K562 cells with an effector:target (10:1) for four hours. Cells were stained with anti-CD16 antibody for the determination of CD107a expression by flow cytometry. Cytotoxic activity (by using CFSE-labeled K562 as target cells), expression of NK cell receptors and surface markers, intracellular IL-5, IL-10, IL-17 and IFN-glevels in CD16<sup>+</sup> NK cells were also determined by flow cytometry. Statistical analyses were performed by Mann Whitney U test. <h3>Results</h3> Although the percentages of NK, CD16<sup>bright</sup>CD56<sup>dim</sup>, CD16<sup>dim</sup>CD56<sup>bright</sup> subsets, NKp46 and NKG2D expressions were found similar in both groups, there was a significant difference in NK cell subsets. IFN-gsecreting NK1 cell subsets were found to be higher in BD group (p=0.001). However, IL-5<sup>+</sup>CD16<sup>+</sup> NK2 cells, IL-17<sup>+</sup>CD16<sup>+</sup> NK17 and IL-10 secreting NK regulatory cell ratio were found significantly decreased in BD group (p=0.001). Although the CD107a expression levels were found decreased in BD group, cytotoxic activity did not show any difference between groups with CFSE method (p=0.03). <h3>Conclusions</h3> We found a polarization to NK1 cell subset in BD. Although no difference was found in the cytotoxic activity, the degranulation ratio of NK cells is significant lower in BD. Our findings revealed that increased NK1 cell subsets might play role in BD pathogenesis. <h3>Disclosure of Interest</h3> None Declared
FRI0514 Severity of knee oa, detected by mri, associated with outcome of exercise therapy?
Authors: J. Knoop, J. Dekker, M. van der Leeden, M. van der Esch, J.-P. Klein, L. D. Roorda, W. F. Lems, M. P. Steultjens
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Severity of knee joint damage is considered a barrier for effective exercise therapy in patients with knee osteoarthritis (OA), although no study evaluated associations between severity of OA-related knee joint tissue abnormalities and outcome of exercise therapy yet. <h3>Objectives</h3> To evaluate associations between severity of OA-related knee joint tissue abnormalities, detected by MRI at baseline, and reductions in activity limitations, reductions in pain, and treatment response (i.e. outcome of exercise therapy) in knee OA patients treated with exercise therapy. <h3>Methods</h3> In 99 patients with knee OA, participating a supervised 12-week exercise program, baseline MRI scans of the knee joint were obtained. BLOKS was used to assess severity of multiple MRI features (bone marrow lesions, cartilage loss, osteophytes, effusion, synovitis and meniscal abnormalities). Regression analyses were performed to analyze associations between severity of multiple MRI features (for tibiofemoral and patellafemoral compartment seperately) and reductions in activity limitations (WOMAC physical function, primary outcome), reductions in pain (NRS) and treatment response according to OMERACT-OARSI responder criteria (secondary outcomes). <h3>Results</h3> Reductions of 24% and 33% in activity limitations (WOMAC) and pain (NRS), respectively, were found in 99 participants following exercise therapy, while two third (67%) could be considered responder according to OMERACT-OARSI responder criteria. Severity of patellafemoral cartilage loss at baseline was negatively associated (B (95% CI) = -4.7 (-2.5- 5.4), p=.01) with outcome of exercise therapy (i.e. less improvements in activity limitations in patients with moderate-severe patellafemoral cartilage loss). Severity in other MRI features were not found to be associated with outcome of exercise therapy. <h3>Conclusions</h3> Severity of knee joint damage does not seem to a barrier for effective exercise therapy in patients with knee OA, except for moderate-to-severe cartilage loss in the patellafemoral compartment. This study suggest that also patients with highest grades of knee OA severity may benefit from exercise therapy. For patients with patellafemoral cartilage defects, exercises may need to be adapted or additional interventions may be necesarry for optimal treatment outcome. <h3>Disclosure of Interest</h3> None Declared
MRP4 EXPRESSION IN PLATELET OF PATIENTS UNDER CHRONIC ASPIRIN TREATMENT IS INFLUENCED BY MICRORNA MODULATION: A NEW MECHANISM FOR ASPIRIN RESISTANCE?
Authors: Luigi M. Biasucci, Claudia Mandolini, Giorgia Copponi, Isabella Massimi, Fabio Pulcinelli, Filippo Crea
Journal: Journal of the American College of Cardiology (2015)